HC Wainwright Issues Pessimistic Forecast for CRBP Earnings

Key Points

• HC Wainwright lowered its FY2026 EPS forecast for Corbus Pharmaceuticals to a loss of $6.61 per share from $6.11, below the consensus loss estimate of $5.89. It maintained a Buy rating and a $35 price target.
• Corbus reported a quarterly loss of $1.81 per share, missing analysts’ expected loss of $1.27 by $0.54.
• Analyst views are mixed: MarketBeat reports a Moderate Buy consensus rating and $38.14 average target price, while one firm rates the stock Sell.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Investment analysts at HC Wainwright decreased their FY2026 EPS estimates for Corbus Pharmaceuticals in a research note issued to investors on Tuesday, November 10th. HC Wainwright analyst A. Maldonado now expects that the biopharmaceutical company will post earnings per share of ($6.61) for the year, down from their previous estimate of ($6.11). HC Wainwright currently has a "Buy" rating and a $35.00 target price on the stock. The consensus estimate for Corbus Pharmaceuticals' current full-year earnings is ($5.89) per share. HC Wainwright also issued estimates for Corbus Pharmaceuticals' Q4 2026 earnings at ($1.73) EPS, FY2027 earnings at ($6.13) EPS, FY2028 earnings at ($5.28) EPS, FY2029 earnings at ($2.19) EPS and FY2030 earnings at ($0.09) EPS.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last posted its quarterly earnings results on Tuesday, November 10th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.54).

• Corbus Pharmaceuticals NASDAQ: CRBP Gives a Bold Buy Signal

Several other equities research analysts also recently commented on the company. Mizuho dropped their target price on Corbus Pharmaceuticals from $24.00 to $23.00 and set an "outperform" rating on the stock in a report on Thursday. Wall Street Zen downgraded Corbus Pharmaceuticals from a "sell" rating to a "strong sell" rating in a report on Saturday, August 8th. Oppenheimer restated an "outperform" rating on shares of Corbus Pharmaceuticals in a report on Wednesday. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Corbus Pharmaceuticals in a research report on Thursday, October 15th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $38.14.

Corbus Pharmaceuticals Stock Up 1.8%

CRBP stock opened at $4.00 on Thursday. The business has a 50 day moving average of $5.99 and a 200 day moving average of $8.40. The firm has a market cap of $74.68 million, a PE ratio of -0.66 and a beta of 2.80. Corbus Pharmaceuticals has a twelve month low of $2.81 and a twelve month high of $12.88.

Hedge Funds Weigh In On Corbus Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE lifted its position in Corbus Pharmaceuticals by 53,592.3% in the 1st quarter. Bank of America Corp DE now owns 13,960 shares of the biopharmaceutical company's stock valued at $131,000 after acquiring an additional 13,934 shares in the last quarter. Ieq Capital LLC bought a new stake in shares of Corbus Pharmaceuticals in the 3rd quarter worth $96,000. Pale Fire Capital SE increased its holdings in shares of Corbus Pharmaceuticals by 14.5% in the 1st quarter. Pale Fire Capital SE now owns 21,350 shares of the biopharmaceutical company's stock worth $200,000 after purchasing an additional 2,700 shares in the last quarter. Engineers Gate Manager LP raised its stake in shares of Corbus Pharmaceuticals by 109.9% in the second quarter. Engineers Gate Manager LP now owns 29,800 shares of the biopharmaceutical company's stock worth $280,000 after purchasing an additional 15,600 shares during the last quarter. Finally, Royal Bank of Canada raised its stake in shares of Corbus Pharmaceuticals by 81.2% in the first quarter. Royal Bank of Canada now owns 29,901 shares of the biopharmaceutical company's stock worth $281,000 after purchasing an additional 13,401 shares during the last quarter. 64.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Corbus Pharmaceuticals

In other news, major shareholder Cormorant Asset Management, Lp sold 425,000 shares of the stock in a transaction that occurred on Thursday, October 29th. The shares were sold at an average price of $4.10, for a total transaction of $1,742,500.00. Following the sale, the insider owned 1,919,971 shares in the company, valued at $7,871,881.10. This represents a 18.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 3.50% of the stock is currently owned by insiders.

Latest Corbus Pharmaceuticals News

Here's some of the latest news about CRBP:

• Positive Sentiment: HC Wainwright raised its estimates for FY2027 and FY2028, forecasting losses of $6.13 and $5.28 per share, respectively. The firm maintained its Buy rating and $35 price target, which offers a counterpoint to the lowered estimates. Corbus Pharmaceuticals coverage
• Negative Sentiment: HC Wainwright cut its Q4 2026 and FY2026 estimates to losses of $1.73 and $6.61 per share, respectively. It also lowered FY2029 and FY2030 forecasts, with the latter shifting from expected earnings of $0.15 per share to a loss of $0.09. The downward revisions reinforce concerns about the company’s path to profitability. Corbus Pharmaceuticals coverage
• Negative Sentiment: Corbus reported a Q3 loss of $1.81 per share, wider than the $1.27 loss analysts expected—a miss of $0.54 per share. The earnings shortfall may add pressure to the stock. Q3 financial results and corporate update

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. is a biopharmaceutical company focused on developing medicines for serious diseases in oncology and immunology. The company's research is centered on therapies designed to modulate immune-cell activity and target biological pathways involved in cancer and inflammatory disease. Corbus' oncology pipeline has included soquelitinib, formerly known as CPI-818, an oral, selective inhibitor of interleukin-2-inducible T-cell kinase (ITK) being evaluated for its potential to treat T-cell lymphomas and other cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.